VRAX Stock Analysis: Buy, Sell, or Hold?
VRAX - Virax Biolabs Group Limited Ordinary Shares
$2.67
-0.18 (-6.32%)
▼
5d:
+4.3%
30d:
-3.96%
90d:
+1363.82%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 01, 2026
18d
Get Alerted When VRAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
ℹ️ NEUTRAL: VRAX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
ℹ️ NEUTRAL: VRAX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VRAX is currently trading at $2.67, which is considered slightly low relative to its 30-day fair value range of $2.65 to $3.04.
Technical Outlook: Technically, VRAX is in a strong uptrend. Immediate support is located at $2.52, while resistance sits at $2.94. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $25.00 (+836.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VRAX is in a strong uptrend. Immediate support is located at $2.52, while resistance sits at $2.94. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $25.00 (+836.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.65 -
$3.04
Company Quality Score
51/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (59/100)
- BEARISH: Downward momentum (-6.3%)
- BULLISH: Trading 836.3% below Wall St target ($25.00)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.65 -
$3.04
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.52
Resistance Level
$2.95
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.45
Wall Street Target
$25.00
(+836.3%)
Revenue Growth (YoY)
684.9%
Share & Embed Analysis
Last updated: September 12, 2026 4:15 AM ET
Data refreshes hourly during market hours. Next update: 5:15 AM
Data refreshes hourly during market hours. Next update: 5:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 48 HOLD |
